For the quarter ending 2026-03-31, GLUE had $29,969K increase in cash & cash equivalents over the period. -$39,237K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -44,503 | -46,135 | -27,081 | 34,590 |
| Stock-based compensation expense | 5,949 | 4,309 | 4,364 | 10,192 |
| Depreciation | 2,029 | 2,088 | 2,095 | 4,173 |
| Net accretion of discounts/premiums on marketable securities | -985 | 87 | -466 | -1,766 |
| Gain on disposal of property and equipment | 0 | 0 | 0 | 59 |
| Collaboration receivable | -7,000 | 7,000 | - | - |
| Other receivables | 9 | -365 | 2,596 | 2,196 |
| Accounts receivable | - | - | - | 0 |
| Prepaid expenses and other assets | 2,921 | -1,376 | -941 | 1,713 |
| Accounts payable | 4,377 | -10,612 | 8,880 | -11,976 |
| Accrued expenses and other current liabilities | -3,712 | 8,735 | 4,194 | -5,077 |
| Defined benefit plan liability | -49 | 147 | -235 | -957 |
| Right-of-use assets and operating lease liabilities | -434 | -298 | -354 | -427 |
| Deferred revenue | -4,209 | 4,218 | 110,216 | -106,910 |
| Net cash used in operating activities | -37,369 | -43,014 | 100,428 | -80,212 |
| Purchases of property and equipment | 1,868 | 767 | 651 | 3,282 |
| Purchases of marketable securities | 331,997 | 153,659 | 65,969 | 157,047 |
| Proceeds from maturities of marketable securities | 72,868 | 89,360 | 104,758 | 85,424 |
| Net cash used in investing activities | -260,997 | -65,066 | 38,138 | -74,905 |
| Proceeds from sale of common stock pursuant to the at-the-market sales agreement, net of underwriter's discount of 29 | - | - | 0 | 0 |
| Proceeds from sale of common stock pursuant to the at-the-market sales agreement, net of underwriter's discount | - | 24,250 | - | - |
| Proceeds from underwritten public offering, net of underwriter's discount of 3,000 | - | 0 | 0 | 0 |
| Proceeds from issuance of pre-funded warrants | - | 0 | 0 | 0 |
| Payment of common stock and pre-funded warrant issuance costs | - | 357 | 0 | 0 |
| Proceeds from exercise of employee stock options | 4,522 | 5,361 | 348 | 14 |
| Proceeds from underwritten public offering, net of underwriter's commission of 20,700 | 324,300 | - | - | - |
| Proceeds from employee stock purchase plan | - | 370 | 0 | 365 |
| Payment of offering costs | 487 | - | - | - |
| Net cash provided by financing activities | 328,335 | 29,624 | 348 | 379 |
| Net decrease in cash, cash equivalents and restricted cash | 29,969 | -78,456 | 138,914 | -154,738 |
| Cash, cash equivalents and restricted cashbeginning of period | 134,837 | 15,824 | 229,117 | - |
| Cash, cash equivalents and restricted cash-end of period | 164,806 | -78,456 | 213,293 | - |
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)